State-of-the-art PET/CT of the pancreas: Current role and emerging indications

Radiographics

Volumn 32, Issue 4, 2012, Pages 1133-1158

  Sahani, Dushyant V ^a   Bonaffini, Pietro A ^b   Catalano, Onofrio A ^c   Guimaraes, Alexander R ^a   Blake, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS SDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; IMAGE ENHANCEMENT; METHODOLOGY; PANCREAS; PANCREAS DISEASE; RADIOGRAPHY; SCINTISCANNING;

HUMANS; IMAGE ENHANCEMENT; PANCREAS; PANCREATIC DISEASES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84863873783     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.324115143     Document Type: Article

References (101)

1. Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004;182(3):619-623.
2. Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr. MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and re se ctability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004;182(2):419-425.
3. Chan SC, Ng SH, Chang JT, et al. Advantages and pitfalls of 18F-fluoro-2-deoxy-d-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2006;33(9):1032-1040.
4. Hong HS, Yun M, Cho A, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med 2010;35(10):776-779.
5. Sperti C, Bissoli S, Pasquali C, et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2007;246(6):932-937; discussion 937-939.
6. Takanami K, Hiraide T, Tsuda M, et al. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant in traductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med 2011; 25(7):501-510.
7. Tomimaru Y, Takeda Y, Tatsumi M, et al. Utility of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 2010;24(3): 613-620.
8. Zamboni GA, Kruskal JB, Vollmer CM, Baptista J, Callery MP, Raptopoulos VD. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology 2007;245(3): 770-778.
9. Fukushima H, Itoh S, Takada A, et al. Diagnostic value of curved multiplanar reformatted images in multislice CT for the detection of resectable pancreatic ductal adenocarcinoma. Eur Radiol 2006;16(8): 1709-1718.
10. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206(2):373-378.
11. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168(6):1439-1443.
12. Manak E, Merkel S, Klein P, Papadopoulos T, Bautz WA, Baum U. Resectability of pancreatic adenocarcinoma: assessment using multidetector-row computed tomography with multiplanar reformations. Abdom Imaging 2009;34(1):75-80.
13. Valls C, Andía E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002;178(4):821-826.
14. Kim T, Murakami T, Takamura M, et al. Pancreatic mass due to chronic pancreatitis: correlation of CT and MR imaging features with pathologic findings. AJR Am J Roentgenol 2001;177(2):367-371.
15. Urban BA, McGhie PA, Fishman EK. Helical CT: diagnostic pitfalls of arterial phase imaging of the upper abdomen. AJR Am J Roentgenol 2000;174 (2):455-461.
16. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242(2): 360-385.
17. Pandit-Taskar N, Schöder H, Gonen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004;183 (4):1143-1147.
18. Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250(6):957-963.
19. Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging 2008;35(10):1775-1785.
20. van Kouwen MC, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005;32(4):399-404.
21. Yoshioka M, Sato T, Furuya T, et al. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-d-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 2004;39(1):50-55.
22. Ruf J, Lopez Hänninen E, Oettle H, et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005;5(2-3): 266-272.
23. Kuwatani M, Kawakami H, Eto K, et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 2009;48(11): 867-875.
24. Sperti C, Pasquali C, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 2010;14(1): 131-140.
25. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238(2):405-422.
26. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231(2):305-332.
27. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39(6):1030-1033.
28. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44(11):1797-1803.
29. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. RadioGraphics 2007;27(1):145-159.
30. Hruban RH, Klimstra DS, Pitman MB. AFIP atlas of tumor pathology: tumors of the pancreas-series 4. Washington, DC: AFIP, 2007; 23-376.
31. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics: 2010. CA Cancer J Clin 2010;60(5):277-300.
32. Howlader N, Noone AM, Krapcho M, et al. Anonymous Surveillance Epidemiology and End Results of the National Cancer Institute. SEER Cancer Statistics Review: 1975-2009. http://seer.cancer.gov/statfacts/html/pancreas.html. Published April 1 2012. Accessed April 30, 2012.
33. Duffy JP, Reber HA. Nonendocrine tumors of the pancreas. In: Yamada T, ed. Textbook of Gastroenterology, 4th edition. Philadelphia, Pa: Lippincott Williams and Wilkins, 2003; 2091-2107.
34. Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140(1):31-35.
35. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of re sectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16(7):1727-1733.
36. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27 (13):2269-2277.
37. Mallery JS, Centeno BA, Hahn PF, Chang Y, Warshaw L Brugge WR. Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity. Gastrointest Endosc 2002;56(2):218-224.
38. Tatli S, Gerbaudo VH, Mamede M, Tuncali K, Shyn PB, Silverman SG. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology 2010;256(1):305-311.
39. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging 2007;32(5):660-667.
40. Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB Jr. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 2002;224(3):764-768.
41. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET): usefulness and limitations inclinical reality". Ann Nucl Med 2003;17(4):261-279.
42. Okano K, Kakinoki K, Akamoto S, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 2011;17(2):231-235.
43. Lemke AJ, Niehues SM, Hosten N, et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J Nucl Med 2004;45(8):1279-1286.
44. Boll DT, Merkle EM. Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol 2003;13(Suppl 5):M42-M49.
45. Koyama K, Okamura T, Kawabe J, et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15(3):217-224.
46. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86(2):194-199.
47. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246(1):52-60.
48. Saif MW, Cornfeld D, Modarresifar H, Ojha B. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J Gastrointestin Liver Dis 2008;17(2):173-178.
49. Soriano A, Castells A, Ayuso C, et al. Preoperative staging and tumor re sectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99(3):492-501.
50. Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242(2):235-243.
51. Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20(2):109-116.
52. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139(11):879-892.
53. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54(4): 248-252.
54. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23(34):8713-8716.
55. Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005;185(1):239-246.
56. Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 2005;19(5):638-642.
57. Tabuchi T, Itoh K, Ohshio G, et al. Tumor staging of pancreatic adenocarcinoma using early- and late-phase helical CT. AJR Am J Roentgenol 1999;173 (2):375-380.
58. Nishiyama Y, Yamamoto Y, Yokoe K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005;19(6):491-497.
59. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40(11):1784-1791.
60. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007;245(4):566-572.
61. Casneuf V, Delrue L, Kelles A, et al. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007;70(4): 331-338.
62. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40(10):923-929.
63. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010;77(5):1420-1425.
64. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol 2011;16(1):39-44.
65. Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. RadioGraphics 2006;26(5):1335-1353.
66. Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011;2(1):28-43.
67. Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM. CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 2007;62(3):371-377.
68. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuro endocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112(11):2447-2455.
69. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2): S51-S61.
70. Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216(1): 163-171.
71. Nakamoto Y, Higashi T, Sakahara H, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 2000;25(2):115-119.
72. Versari A, Camellini L, Carlinfante G, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010;35(5): 321-328.
73. Nayer H, Weir EG, Sheth S, Ali SZ. Primary pancreatic lymphomas: a cytopathologic analysis of a rare malignancy. Cancer 2004;102(5):315-321.
74. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107(1):175-183.
75. Martin DR, Semelka RC. MR imaging of pancreatic masses. Magn Reson Imaging Clin N Am 2000;8 (4):787-812.
76. Yoon SN, Lee MH, Yoon JK. F-18 FDG positron emission tomography findings in primary pancreatic lymphoma. Clin Nucl Med 2004;29(9):574-575.
77. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16(9):1514-1523.
78. Ghavamian R, Klein KA, Stephens DH, et al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc 2000;75 (6):581-585.
79. Sato M, Okumura T, Kaito K, et al. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer. Ann Nucl Med 2009;23(1): 49-57.
80. Merkle EM, Boaz T, Kolokythas O, Haaga JR, Lewin JS, Brambs HJ. Metastases to the pancreas. Br J Radiol 1998;71(851):1208-1214.
81. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL. Cystic neoplasms of the pancreas. N Engl J Med 2004;351(12):1218-1226.
82. Takeshita K, Kutomi K, Takada K, et al. Unusual imaging appearances of pancreatic serous cystadenoma: correlation with surgery and pathologic analysis. Abdom Imaging 2005;30(5):610-615.
83. Sahani DV, Sainani NI, Blake MA, Crippa S, Mino-Kenudson M, del-Castillo CF. Prospective evaluation of reader performance on MDCT in characterization of cystic pancreatic lesions and prediction of cyst biologic aggressiveness. AJR Am J Roentgenol 2011;197(1):W53-W61.
84. Sainani N, Sahani DV, Blake M, Deshpande V, Fernandes-del Castillo C, Fischman A. Morphological and functional characterization of mucinous lesions of pancreas: is the combination PET-CT better than MDCT or PET alone? J Nucl Med Meeting Abstracts 2008;49:273P-a.
85. Whitcomb DC. Clinical practice Acute pancreatitis. N Engl J Med 2006;354(20):2142-2150.
86. Owyang C, Levitt M. Chronic Pancreatitis. In: Yamada T, Alpers DH, Owyang C, Powell DH, Silverstein FE, eds. Textbook of gastroenterology. Volume 2. New York, NY: JB Lippincott, 1991; 1874-1893.
87. Vlachou PA, Khalili K, Jang HJ, Fischer S, Hirschfield GM, Kim TK. IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. RadioGraphics 2011;31(5): 1379-1402.
88. Kamisawa T, Takum K, Anjiki H, et al. FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 2010;57(99-100):447-450.
89. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010;34(12):1812-1819.
90. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med 2006; 355(25):2670-2676.
91. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006;4(8):1010-1016; quiz 934.
92. Lee TY, Kim MH, Park H, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pan creatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 2009;193(2):343-348.
93. Jeong Yoon S, Lee B, Park CH. Imaging diagnosis of post-ERCP focal pancreatitis mimicking pancreatic carcinoma by follow-up F-18 FDG PET/CT. Clin Nucl Med 2011;36(1):70-72.
94. Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med 2010;21 (3):216-221.
95. Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 2008;43 (2):144-151.
96. von Forstner C, Egberts JH, Ammerpohl O, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49(8): 1362-1370.
97. Buck AK, Kratochwil C, Glatting G, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 2007;34(11):1775-1782.
98. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45(4):695-700.
99. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47(1):150-154.
100. Malesci A, Balzarini L, Chiti A, Lucignani G. Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion. Eur J Nucl Med Mol Imaging 2004;31(9):1352.
101. Tatsumi M, Isohashi K, Onishi H, et al. 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol 2011;16(4):408-415.